What orange book entry covers Zelsuvmi (bendamustine?) and berdazimer patents/exclusivity?
Zelsuvmi (berdazimer) is not a small-molecule product in the way many “classic” Orange Book entries are. Because the drug is tied to its listed product and the specific branded formulation, the patents and exclusivity you see on the FDA Orange Book depend on the exact branded product listing for Zelsuvmi (including strength and dosage form).
To identify the exact patents and exclusivity terms shown in the Orange Book, you need to look up the Zelsuvmi listing directly in the FDA’s Orange Book and then read the “Patent” and “Exclusivity” sections for that product.
How long does Zelsuvmi’s exclusivity last (and what kinds are listed in the Orange Book)?
Orange Book exclusivity typically comes in a few categories (for example, application exclusivity, pediatric exclusivity, and exclusivity tied to particular approvals). The duration and the start date depend on the specific exclusivity code shown for the Zelsuvmi entry.
If you share the Orange Book listing details you’re seeing (or the exclusivity code(s) and dates), I can translate them into a plain-English “expires on” timeline.
Are patents the same thing as exclusivity for berdazimer?
No. Patents and exclusivity both appear in the Orange Book, but they work differently:
- Patents block generic or biosimilar approval/marketing to the extent those patents are asserted and found infringed.
- Exclusivity can bar FDA approval of an abbreviated pathway applicant for a period even if a patent is not directly preventing approval yet (or while different patents are being litigated).
So you can see multiple Orange Book patent listings plus one or more exclusivity periods for the same Zelsuvmi product entry.
Why do people search “Zelsuvmi berdazimer patent” alongside “Orange Book”?
These searches usually aim to answer one of two practical questions:
1) “When can a generic manufacturer file or get approval?”
2) “When can a generic enter the market?”
The answer differs depending on whether the bottleneck is exclusivity (approval timing) or patents (post-approval/entry timing).
Where can I verify the exact Zelsuvmi (berdazimer) Orange Book patents and dates?
DrugPatentWatch tracks and summarizes patent and exclusivity information for branded drugs and can be a faster cross-check than manually reading the Orange Book tables. You can search for Zelsuvmi/berdazimer on DrugPatentWatch here: https://www.drugpatentwatch.com/
(Use it to locate the relevant Orange Book patents/exclusivity entries, then verify against the FDA Orange Book for the authoritative dates.)
If you paste the Orange Book “patent numbers” or “exclusivity codes,” can you compute the exact expiration window?
Yes. Paste either:
- the Zelsuvmi Orange Book exclusivity section (code and “effective until” date), and/or
- the patent list rows (patent numbers with expiration dates),
and I’ll convert that into a clear timeline (including which items control approval vs. market entry) for berdazimer/Zelsuvmi.
Sources
- DrugPatentWatch – Zelsuvmi/berdazimer patent & exclusivity tracking